Stargen

Quick links to important sections

Stargen

Treatment option: Creatinine, Cystinuria

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stargen

Quick Facts

Property Description
Active ingredient Tiopronin (N-(2-Mercaptopropionyl) glycine)
Form Oral tablet (immediate-release or delayed-release)
Pharmacological class Cystinuria Agent / Miscellaneous Genitourinary Agent
Common use Managing high urinary cystine levels
Origin Synthetic small molecule

What is Stargen?

The drug Stargen is a prescription-only medication primarily used as a second-line therapy to manage severe hereditary conditions affecting the urinary system. Its active component is Tiopronin (N-(2-Mercaptopropionyl) glycine), which is a synthetic small molecule compound. Stargen is classified pharmacologically as a Cystinuria Agent, a specialized type of Miscellaneous Genitourinary Tract Agent, a designation that immediately identifies its primary role in chemical management.

Unique Profile and Composition

Tiopronin functions as a thiol drug and is a single-ingredient product delivered orally as a tablet. Stargen formulations include both an immediate-release preparation and a specialized gastro-resistant delayed-release form, which helps manage its delivery within the digestive tract. This medicine is primarily recognized for its application in treating severe homozygous cystinuria, a use that is clinically recognized within specialized pharmacological studies.

General Purpose and Mechanism Summary

Stargen’s general purpose is to chemically reduce the concentration of insoluble cystine in the urine. By acting as a reducing agent, Tiopronin chemically binds with cystine—a substance poorly soluble in urine that aggregates into stones—to create a new, highly water-soluble mixed disulfide complex. This mechanism effectively minimizes the risk of crystalline aggregation and the formation of kidney stones, which is critical for managing the clinical symptoms of the disorder.

Regulatory References

  1. National Library of Medicine

What side effects are possible with Stargen?

Possible side effects and safety information

The safety profile of Stargen (tiopronin) is formally documented in government regulatory labeling, categorizing potential adverse reactions by body system and frequency of occurrence. The information below reflects findings from clinical studies and post-marketing surveillance, as defined by official health authorities.

Officially Documented Adverse Reactions

The most frequently observed adverse reactions, reported in ge 10% of patients in clinical trials, often involve the digestive system and skin.

Classification Examples of Reactions
Most Common (ge 10% ) Nausea, diarrhea or soft stools, oral ulcers, rash, fatigue, fever, arthralgia (joint pain), proteinuria, and emesis (vomiting).
Other Reported Reactions Anemia, pruritus, urticaria, peripheral edema, weakness, and skin wrinkling.

Serious Safety Considerations

Official labeling highlights the potential for serious adverse reactions. Tiopronin has been associated with the risk of proteinuria, including severe forms such as nephrotic syndrome and membranous nephropathy. Cases of severe hypersensitivity reactions are documented, which may involve drug fever, arthralgia, and rash. Cases of acute renal failure and rare blood disorders, such as agranulocytosis and aplastic anemia, have also been reported in post-marketing experience.

Population-Specific Safety Notes

Specific safety considerations are noted for certain patient groups. Pediatric patients may face an increased risk of proteinuria when receiving an active ingredient dosage exceeding 50 mg/kg per day. In geriatric patients, caution is recommended due to the higher likelihood of reduced kidney function. Furthermore, regulatory guidelines state that breastfeeding is not recommended during treatment.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose for Stargen (Tiopronin) is strictly derived from official government regulatory documents.

Documented Overdose Profile

Element Regulatory Documentation Summary
Documented Manifestations Official labeling does not list specific, acute clinical manifestations or distinct symptoms resulting from an acute overdose.
Antidote Information No specific antidote is known for tiopronin overdose.
Life-Threatening Risk Overdose has resulted in no reported deaths specifically attributed to tiopronin. However, due to its structural class, regulators note a theoretical risk of severe or fatal outcomes, including serious hematologic and autoimmune complications.

Required Emergency Action

Immediate medical attention or contact with emergency services is required upon any suspicion of an acute overdose. Management of the condition is officially limited to providing symptomatic and supportive treatment within a controlled environment.

Because of the potential for severe, class-related adverse effects, hospital monitoring may be necessary. This observation includes monitoring hematologic parameters and renal status to detect complications like aplastic anemia or significant proteinuria, as stated in prescribing information.

Therapeutic Uses of Stargen

Tiopronin is used as a specialized agent for the long-term management of a rare, inherited metabolic disorder, and is applied across domains where additional symptomatic support is needed. This medication is applied to help with the prevention of cystine stone formation in adult and pediatric patients (20 kg and greater) with severe homozygous cystinuria. It is generally used as a second-line pharmacological agent in situations where conservative measures like high fluid intake, diet modification, and urinary alkalization have been insufficient.

Key Therapeutic Focus

Tiopronin is relevant in conditions characterized by recurrent or episodic manifestations of urolithiasis, which involves symptoms related to physical discomfort and organ-specific functional stress. The medication plays a role in managing the symptoms related to stone formation, such as flank pain (renal colic), hematuria, and the risk of secondary urinary tract infections (UTIs).

“By supporting stone prevention, it may assist with maintaining functional stability and may help to ease the overall symptom load.”

This provides support that helps ease the overall symptom burden, and may assist with reducing the strain associated with the need for repeated, invasive surgical stone removal procedures over time.


Quick Fact: Relief for Recurrent Stone Formation Property Description
Primary Use Stone Prevention (Cystinuria)
Clinical Context Chronic, second-line management
Symptom Focus Flank pain, Hematuria, UTIs
Patient Benefit Supports stability, eases symptom burden

Regulatory References

  1. DailyMed (NIH/FDA) Prescribing Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Stargen?

Eligibility for Stargen (Tiopronin) is strictly defined by regulatory authorities and centers on age, weight, hypersensitivity, and specific organ function status. The medication is indicated for adults and pediatric patients who weigh 20 kg and greater with severe homozygous cystinuria, provided they have not responded sufficiently to conservative measures like high fluid intake and diet modification.

Contraindications and Restrictions

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity (severe allergic reaction) to tiopronin or any other component of the medicine.
Mandatory Discontinuation Patients who develop proteinuria (including nephrotic syndrome) during treatment.
Use Not Established Pediatric patients weighing less than 20 kg.
Not Recommended Breastfeeding women (due to the potential for serious adverse reactions in the infant).

Use in older adults requires careful dose selection and monitoring of renal function due to the increased likelihood of decreased kidney function in that population.

What should I know about interactions with other medicines?

The official regulatory profile for Stargen (Tiopronin) details a highly specific set of restrictions, characterized primarily by the absence of known clinically significant drug-drug interactions. Government prescribing information confirms that Tiopronin has no documented metabolic interactions involving major Cytochrome P450 enzymes or drug transporters.

The single non-medicinal substance interaction identified is with Alcohol (Ethanol), which exclusively affects the delayed-release tablet formulation. This interaction is pharmacokinetic in nature: co-administration with alcohol causes a faster rate of drug release from the tablet. To manage this altered drug exposure profile, the label mandates a strict timing rule: alcohol consumption must be avoided for two hours before and three hours after taking the delayed-release tablet.

For the immediate-release tablet formulation, the official documents establish a crucial administration timing requirement in relation to food to ensure proper absorption. The dose must be separated from meals by being administered at least one hour before or two hours after consumption of food.

No other formal interactions with herbal products or supplements are officially documented. The regulatory profile also contains no specific warnings regarding population-dependent differences in interaction severity.

Mechanism of Action

Molecular Transformation and Thiol-Disulfide Exchange

The mechanism of action for Stargen (Tiopronin) is a highly specific chemical transformation, focused entirely on a single target molecule in the urine, distinct from drug mechanisms that involve receptors or enzymes. The core action is a direct chemical interaction where the drug's reactive thiol ( R- SH) group attacks the disulfide bond ( -S- S-) of the urinary solute, Cystine. This process, known as thiol-disulfide exchange, converts the insoluble target molecule into a new, highly water-soluble mixed disulfide complex. The reaction converts the low-solubility solute into a high-solubility complex.

Inhibiting Crystallization through Solubility Modulation

This chemical conversion directly modulates the physical chemistry of the urine by reducing the concentration of free, insoluble Cystine. The formation of the soluble complex is the primary mechanism that ensures the concentration of the insoluble solute remains below the critical point of supersaturation, which is necessary for the nucleation and growth of crystals. The physiological effect is the inhibition of physical aggregation, maintaining a more favorable solubility profile within the urinary tract.

Mechanistic Specificity and Limitations

The drug exhibits high specificity, as its action is limited to molecules containing the disulfide bond. Consequently, the mechanism acts to inhibit new crystallization—but its ability to break down or dissolve large, pre-existing aggregates is significantly limited. This specificity constrains its physiological scope solely to altering the solubility of the target solute.

Dosage and Administration Information

Stargen is an oral medication available as an Immediate-Release (IR) tablet or a Delayed-Release (EC) tablet and is administered in three equally divided doses daily (TID). This standardized frequency is established to maintain consistent systemic levels.

Dosage and Frequency

The starting dose for adults is typically 800 mg per day, while pediatric patients weighing 20 kg or greater begin with a weight-based dose of 15 mg/kg per day. Use is not approved for pediatric patients weighing less than 20 kg.

Administration Timing and Preparation

Administration instructions are specific to the formulation. The IR tablet requires dosing on an empty stomach (at least one hour before or two hours after a meal) to ensure proper delivery. The EC tablet, however, may be taken with or without food, although maintaining a consistent meal routine is advised. In general, tablets must be swallowed whole. An exception exists for the EC tablet, which can be crushed and mixed with a tablespoon of applesauce for patients with swallowing difficulty; this mixture must be administered immediately. Patients taking the EC form should also avoid alcohol consumption for several hours around the time of dosing.

Titration Protocol

The medicine is managed through a long-term titration protocol. Following initiation, the dose is systematically adjusted to maintain the urinary cystine concentration below 250 mg/L. This adjustment requires procedural monitoring: 24-hour urinary cystine levels are measured one month after starting treatment and then every three months to guide any necessary dosage modifications.

Recent Clinical Evidence

Research Evidence for Stargen (Tiopronin)

This overview provides a summary of the official research evidence and study landscape for Stargen, focusing on the types of studies that have been conducted and the broad findings reported to regulatory authorities. This information is purely descriptive and does not offer clinical advice, specific usage instructions, or treatment recommendations.


Evidence for Use in Preventing Recurrent Cystine Stones

Research for Stargen was conducted in the context of severe homozygous cystinuria, a condition characterized by fluctuating or episodic manifestations of recurrent kidney stones. The main body of evidence describing its clinical evaluation consists of long-term observational studies and detailed retrospective cohort analyses, which follow groups of patients over defined time intervals. Randomized Controlled Trials (RCTs) specifically assessing hard, long-term stone recurrence outcomes are limited.

Researchers primarily monitored short-term changes in a key biomarker: how much cystine is excreted in the urine. They also examined clinical endpoints, such as the rate of new stone formation and how often patients needed to undergo invasive stone removal procedures. Findings from these long-term observational studies described how the frequency of stone events evolved over time.


Key Limitations and Areas of Uncertainty

Official regulatory assessments indicate that the evidence base for Stargen is considered Moderate. This level reflects the consistency of its underlying data and supportive long-term observational information, balanced against the need for higher-quality evidence.

Key limitations cited in scientific literature include:

  • Sample sizes were modest in most efficacy studies, which is typical for rare diseases.
  • Comparative evidence is lacking, meaning there is limited information comparing Stargen directly to alternative treatments in head-to-head, randomized trials.
  • The overall research depends on non-randomized data (observational and retrospective studies) for long-term clinical assessments, and large-scale, long-term, controlled RCTs are limited.

Key Studies & References

  1. Tiopronin Tablets (U.S. National Library of Medicine, DailyMed)
  2. Medical management of cystinuria: A review of the American Urological Association guideline

Frequently Asked Questions (FAQ)

Common questions about Stargen (FAQ)


Q: How is Stargen different from other medicines used for the same thing?

Official research indicates that direct studies comparing Stargen to all alternative treatments are limited. The medicine's action is highly specific, relying on a chemical process called thiol-disulfide exchange. This process converts the insoluble solute (cystine) in the urine into a new, highly water-soluble complex, unlike drugs that primarily target cell receptors or enzymes.


Q: What should I expect the first time I take Stargen?

According to the official product information, common reactions observed in clinical studies involved the digestive system, such as nausea, diarrhea, or vomiting. Other frequently reported reactions included fatigue, skin rash, and oral ulcers. These are general findings from studies and may not represent individual experiences.


Q: Does Stargen interact with common painkillers like ibuprofen?

Official regulatory labeling confirms that Stargen has no documented metabolic interactions involving major enzyme systems within the body. Regulatory documents state that no formal interactions with common over-the-counter painkillers or herbal supplements are officially documented.


Q: Can Stargen affect my ability to drive or operate machinery?

Studies report side effects such as fatigue and weakness in some patients. Because these types of reactions can affect a person's ability to concentrate or react, individuals who experience them may need to exercise caution when operating heavy machinery or driving.


Q: Has Stargen been studied in pregnant or breastfeeding women?

Regulatory documents contain warnings against use during breastfeeding due to the potential for adverse reactions in the infant. While controlled data in pregnant human populations are limited, official risk assessments state that animal studies indicated potential interference with fetal viability at high doses.


Q: What happens if I accidentally take two doses of Stargen close together?

Regulatory documents do not offer specific guidance regarding a minor, accidental excess dose. In the case of any suspected overdose or severe reaction, the official safety profile suggests monitoring for signs related to known serious adverse effects, such as acute kidney injury or severe hypersensitivity reactions.


Q: Is Stargen meant to be taken indefinitely?

The condition Stargen is used to manage is a severe, chronic hereditary disorder. Therefore, the official protocol for Stargen involves a long-term titration process with continuous monitoring over extended time intervals to maintain chemical management of the condition.


Q: What are the most common reasons patients stop taking Stargen?

The most frequently observed side effects in clinical trials were related to the digestive system and skin, which are often reasons for discontinuation. Furthermore, official eligibility criteria identify conditions, such as the development of proteinuria (excess protein in the urine), that require the medicine to be discontinued.


Q: What is the benefit of Stargen compared to non-drug treatments?

According to the medicine’s indication, Stargen is prescribed when individuals with severe homozygous cystinuria have not responded sufficiently to conservative measures. These conservative measures include high fluid intake and diet modification alone.


Q: Are allergic reactions to Stargen common?

A rash was a common reaction observed in clinical studies, reported in 10% or more of patients. It is also noted that severe, systemic hypersensitivity reactions are documented in the official labeling as a serious safety consideration.


Q: How long does the effect of Stargen last after taking a dose?

The medicine is prescribed in three equally divided doses daily to maintain consistent levels of the active drug in the body. The dosing frequency is designed to ensure the chemical effects receive frequent replenishment to ensure stable management of the target solute concentration throughout the day.


Q: Is Stargen a common type of medication?

Stargen is prescribed as a second-line therapy for a severe hereditary condition. The active ingredient is classified as an orphan drug, a designation used by regulatory authorities for medicines developed specifically to treat rare diseases.


Q: Does Stargen start working immediately?

The core chemical action that makes the target solute more soluble is a direct and immediate process. However, the official dose adjustment protocol requires a one-month period before the first measurement of 24-hour urinary levels is taken to assess therapeutic management.


Q: Can Stargen cause weight changes?

Post-marketing reports have included observations of weight changes, including both weight gain and weight loss. However, these reports are separate from the main clinical trial data, and therefore the established frequency of weight-related reactions is not known.


Q: Are there any studies comparing Stargen to a placebo?

Official regulatory assessments note that Randomized Controlled Trials (RCTs) specifically focused on long-term stone recurrence outcomes are limited. The main body of evidence relies instead on long-term observational studies and retrospective analyses to describe clinical progress.


Q: Is Stargen available as a generic medicine?

Regulatory documents confirm that the active ingredient, Tiopronin, is available in generic form. The FDA has approved generic versions of both the immediate-release and the delayed-release formulations of the tablet.


Q: Is Stargen considered a controlled substance?

According to official regulatory scheduling information in the United States, the active ingredient (Tiopronin) is not classified as a controlled substance.


Q: Can Stargen affect my mood?

Reactions affecting the nervous system, such as confusion and nervousness, have been noted in post-marketing reports from users. However, the official clinical trial data does not establish the frequency of these types of mood-related reactions.


Q: Are there different strengths of Stargen available?

The active ingredient is officially available in multiple tablet strengths. Official labeling confirms that 100 mg and 300 mg strengths are available for the different oral formulations of the medicine.


Q: What is the difference between a side effect and a drug interaction?

A side effect is a reaction that occurs within the body solely from taking the medicine. A drug interaction describes a change in the medicine’s expected effect or the body’s reaction when that medicine is taken alongside another specific substance, such as another drug, supplement, or food.


Q: Can Stargen impact fertility?

The official prescribing information contains specific data regarding the potential for impairment of fertility. This information is typically based on reproductive toxicity studies conducted in animals. Any findings related to human reproductive capacity are formally described in this section of the drug label.


Q: Is Stargen known to cause issues with blood pressure?

Blood pressure issues are not listed as a common or frequent side effect of the medicine. However, an increase in blood pressure has been reported in connection with rare, serious kidney complications, such as Goodpasture syndrome.


Q: What are the signs of overdose described for Stargen?

The official safety profile for the medicine notes that in the event of suspected overdose, monitoring for signs related to the most severe adverse reactions is appropriate. These serious reactions can include symptoms of acute kidney injury, severe allergic reactions, or blood disorders.

How should Stargen be stored and disposed of?

How to Store and Dispose of Stargen (Tiopronin)

Official regulatory documents define specific requirements for the storage and disposal of Tiopronin tablets.

Storage Requirements

Intact tablets must be stored at Controlled Room Temperature, which is 25 C (77 F), with temporary variations permitted between 15 C and 30 C (59 F and 86 F). The product must be stored in its original, tightly closed container and kept out of the sight and reach of children.

Stability and Disposal

A crushed tablet mixed with applesauce for administration has a limited stability period of two hours; the mixture must be stored in a refrigerator during this time and discarded if unused. Unused or expired whole tablets must be disposed of according to official non-flush list guidelines for household trash (mixed with an unappealing substance and sealed) if a take-back program is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stargen found in:

A-Z Index: